Base de dados : LILACS
Pesquisa : D23.101.140 [Categoria DeCS]
Referências encontradas : 1018 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 102 ir para página                         

  1 / 1018 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-983736
Autor: Lima, Jacqueline Silva Brito; Miola, Anna Carolina; Marques, Mariângela Esther Alencar; Miot, Hélio Amante.
Título: Patterns of proliferation and apoptosis in different subtypes of basal cell carcinoma, adjacent epidermis, and recurrent forms
Fonte: An. bras. dermatol;94(1):108-110, Jan.-Feb. 2019. tab, graf.
Idioma: en.
Descritores: Neoplasias Cutâneas/patologia
Carcinoma Basocelular/patologia
Epiderme/patologia
-Imuno-Histoquímica
Biomarcadores Tumorais/análise
Estudos Transversais
Análise Multivariada
Proteína Supressora de Tumor p53/análise
Apoptose
Antígeno Ki-67/análise
Proliferação Celular
Subunidade p50 de NF-kappa B/análise
/análise
FREEZE FRACTURINGABBREVIATIONS AS TOPIC/análise
Limites: Seres Humanos
Masculino
Feminino
Meia-Idade
Idoso
Tipo de Publ: Carta
Responsável: BR1.1 - BIREME


  2 / 1018 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-837949
Autor: Weimann, Ellem Tatiani de Souza; Botero, Erica Bruder; Mendes, Cinthia; Santos, Marcel Alex Soares dos; Stelini, Rafael Fantelli; Zelenika, Caroline Romanelli T.
Título: Cutaneous metastasis as the first manifestation of occult malignant breast neoplasia
Fonte: An. bras. dermatol;91(5,supl.1):105-107, Sept.-Oct. 2016. tab, graf.
Idioma: en.
Resumo: Abstract Cutaneous metastases from primary internal malignancies represent 0.7-9% of patients with cancer. We report a 65-year-old female patient referred for evaluation of normochromic papules on the trunk and upper limbs that had been present for three months. A skin biopsy revealed diffuse cutaneous infiltration by small round cell tumors. Immunohistochemistry was positive for AE1/AE3, CK7, estrogen receptor and mammaglobin. The final diagnosis was cutaneous metastasis of occult breast cancer, since the solid primary tumor was not identified. The location of the primary tumor can not be determined in 5-10% of cases. In these cases, 27% are identified before the patient’s death, 57% at autopsy, and the remaining 16% can not be located.
Descritores: Neoplasias Cutâneas/secundário
Neoplasias Primárias Desconhecidas/patologia
Neoplasias da Mama/patologia
Carcinoma/secundário
-Pele/patologia
Neoplasias Cutâneas/patologia
Biópsia
Imuno-Histoquímica
Biomarcadores Tumorais/análise
Limites: Seres Humanos
Feminino
Idoso
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  3 / 1018 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-792425
Autor: Sehitoglu, Ibrahim; Bedir, Recep; Cure, Erkan; Cure, Medine Cumhur; Yuce, Suleyman; Dilek, Nursel.
Título: Evaluation of the relationship between c-Kit expression and mean platelet volume in classic Kaposi's sarcoma
Fonte: An. bras. dermatol;91(4):430-435, July-Aug. 2016. tab, graf.
Idioma: en.
Resumo: Abstract: Background: c-Kit is a proto-oncogene that encodes tyrosine kinase receptor (CD117). Mean platelet volume (MPV) is a useful marker, providing information on platelet function and diameter. Objective: To investigate c-Kit expression and intensity in patients with Kaposi's sarcoma (KS) and to investigate the relation between Ki-67 proliferation and MPV. Methods: A total of 32 patients, diagnosed with classic cutaneous KS, were included in this study. We reevaluated the histopathological reports with the preparations, confirmed the diagnosis and then determined the patients' histopathological stages. c-Kit expression and Ki-67 proliferation were investigated immunohistochemically in KS cases, while MPV in all cases was checked. Results: Although c-Kit expression was detected in 22 cases (68.8%), it was not expressed in 10 cases (31.2%). We detected 8 cases with + (25%), 6 with ++ (18.8%) and 8 with +++ (25%). Ki-67 expression was 5.0% (min-max 1.0-20.0). Relapse was observed in 5 cases (15.6%) out of 32. There was positive correlation between c-Kit expression and MPV (rs=0.598, p<0.001), and between c-Kit intensity and MPV (rs=0.588, p<0.001). Conclusion: c-Kit is highly positive in KS. c-Kit positivity indicates a high risk of tumor growth, invasion and relapse. Furthermore, c-Kit expression stimulates megakaryocytes to release young and large thrombocytes into the periphery. Thus, high MPV, c-Kit expression and immunostaining intensity indicate high invasion and relapse in KS subjects.
Descritores: Sarcoma de Kaposi/patologia
Neoplasias Cutâneas/patologia
Proteínas Proto-Oncogênicas c-kit/análise
Antígeno Ki-67/análise
Volume Plaquetário Médio
-Valores de Referência
Plaquetas/patologia
Imuno-Histoquímica
Biomarcadores Tumorais
Fatores Sexuais
Estatísticas não Paramétricas
Recidiva Local de Neoplasia/patologia
Estadiamento de Neoplasias
Limites: Seres Humanos
Masculino
Feminino
Adulto
Meia-Idade
Idoso
Idoso de 80 Anos ou mais
Responsável: BR1.1 - BIREME


  4 / 1018 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: lil-442806
Autor: Blas, M; Velázquez, G; Cabral, M.
Título: Valores de referencia del antígeno prostático específico / Refence values of prostate specific antigen
Fonte: Mem. Inst. Invest. Cienc. Salud (Impr.);3(1):23-27, dic. 2005. tab, graf.
Idioma: es.
Resumo: En el presente estudio se determinaron los valores de referencia del PAS (antígeno prostático específico) en individuos en estado de salud para patologías prostáticas, teniendo en cuenta la falta de información en individuos en estas condiciones. Se incluyeron en el estudio, 618 individuos del sexo masculino, con edades comprendidas entre 40 y 69 años, que concurrieron al laboratorio “Medical Center” entre 1999 y 2001, procedentes de consultorios urológicos, con solicitudes de estudios laboratoriales. Para la selección de los individuos se siguieron las recomendaciones del Panel de Expertos en Teoría de los Valores de Referencia de la IFCC (Federación Internacional de Química Clínica). Individuos sin patología prostática, clínicamente sin dificultad en la micción y examen dígito rectal normal, con resultados negativos a los auxiliares de diagnóstico citoscopía y ecografía. Se realizó la medición con el método inmunoensayo de partículas (MEIA), IMX Abbott, USA. En primer término se analizó el tipo de distribución de los valores de concentración de PAS de todos los individuos, empleando el test de Kolmogorov ­ Smirnov. Los valores de referencia de PAS obtenidos, entre los percentiles 2,5% y 97,5% mostraron diferencias de valores por grupo etário, con aumento progresivo (Kruskall­Wallis, p<0,0001). Los valores de referencia del PAS en ng/mL, fueron: de 40 a 49 años de 0,25 a 2; de 50 a 59 años de 0,64 a 3,24; de 60 a 69 años de 0,54 a 3,7. Los valores obtenidos servirán de guía para aplicar criterios de medicina preventiva que ayudaran al profesional de la salud en el diagnóstico precoz de patología prostática.

Development of prostate hyperplasia is an almost universal phenomenon in aging men. The PSA levels in serum are useful in the clinical evaluation in men over the age of 45. The objective of this study was to establish the reference values of prostate specific antigen (PSA) in serum in a selected Paraguayan population by microparticle enzimoimmunoassay MEIA. Six hundred eighteen people were evaluated with ages ranging from 40 to 69 years old who attended to “Laboratory Medical Center” in Asunción, Paraguay during 1999­2001. All were subjected to digital rectal examination, biopsy and echograph to assure the prostate disease free state. The International Federation of Chemical Chemistry (IFCC) reference value guidelines were used for individual selection. PSA concentrations were determined by microparticle enzimoimmunoassay (Autoanalyzer IMXABBOT/USA). The PSA concentration was presented as percentiles since neither the values nor the logarithms fitted into a normal distribution (Kolmogorov­Smirnov Test). Therefore, a nonparametric test (Kruskal­Wallis) was used for the estimation of differences between datum groups. According to age, our data showed statistical differences (p<0,0001). At increasing levels of PSA: 40 ­ 49 years old the serum value ranged from 0.25 ­ 2.0 ng/mL, 50 ­ 59 years old from 0.64 to 3.24 ng/mL and 60 ­ 69 from 0.54 to 3.7 ng/mL. These data represented the percentiles 2.5% and 97.5%. These PSA reference values will serve in screening programs as tools to detect prostate diseases in our population.
Descritores: Antígeno Prostático Específico
Biomarcadores Tumorais
Responsável: PY3.1 - Biblioteca


  5 / 1018 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-838005
Autor: Campagnolo, Orley Alvaro; Morais, Carlos Floriano de; Ughini, Marina Ochoa; Aoki, Camile Mayumi; Menegazzo, Marília.
Título: Dermatomyofibroma
Fonte: An. bras. dermatol;92(1):101-103, Jan.-Feb. 2017. tab, graf.
Idioma: en.
Resumo: Abstract: We report a case of dermatomyofibroma that, to our knowledge, is the second case reported in Brazil. About 100 cases have been reported worldwide. Dermatomyofibroma represents a rare, benign mesenchymal neoplasm of fibroblastic/myofibroblastic differentiation, with prolonged evolution and little or no symptoms. It most commonly occurs in young women and male children. Dermatomyofibroma can be easily confused with other clinical entities, which could lead to unnecessary treatments. Therefore, it is important that dermatologists and pediatricians suspect and start to consider this hypothesis in their diagnostic exercises.
Descritores: Neoplasias Cutâneas/patologia
Histiocitoma Fibroso Benigno/patologia
-Imuno-Histoquímica
Biomarcadores Tumorais
Limites: Seres Humanos
Feminino
Adulto
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  6 / 1018 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1049970
Autor: Sihui, Li; Wenju, Li; Kofi, Arhin Samuel; Yu, Zhao; Linzhi, Yan; Yijie, Chen; Luyi, Li; Ledan, Wang; Jieqiang, Lv.
Título: Identification of High-affinity Novel Targeted Peptides for the Treatment of Human Ovarian Cancer
Fonte: Prensa méd. argent;105(11):816-826, dic2019. fig, tab, graf.
Idioma: en.
Resumo: Background: To investigate the potential of the phage display-identified tumor cellbinding peptide as a biomarker of epithelial ovarian cancer using phage display technology. Method: The Ph.D.-7 Phage Display Peptide Library was used to identify the specific conjugated phages with SKOV3 epithelial ovarian cancer cells, while Chinese hamster ovary cells formed the basis. After employing the rapid differential screening method invitro, the enzyme-linked immunosorbent assay (ELISA), DNA sequencing, immunohistochemistry, immunofluorescence, and the competitive inhibition test of synthetic peptides were used to determine the affinity and specificity of the phages with SKOV3 cells. Results: Using bio panning, we screened the phages, showing a 3590-fold increase after the third round. A total of 61 titers of the phage were randomly selected for ELISA and 10 kinds of the phages with an optical density >0.5 were used for DNA sequencing. Clones of the phage TRRNIPN were derived from DNA sequencing based on ELISA, exhibiting both the brown granular phenomenon and green fluorescence. The specific targeted peptide TRRNIPN was incorporated in tumor cells through the competitive inhibition test. Conclusion: The results of our study indicate that the phage display identified polypeptide TRRNIPN may be an effective biomarker for the early diagnosis and targeted therapy of ovarian cancer
Descritores: Bacteriófagos
DNA/análise
Ensaio de Imunoadsorção Enzimática
Biomarcadores Tumorais
Programas de Rastreamento/métodos
Biblioteca de Peptídeos
Diagnóstico Precoce
Relatório de Pesquisa
/terapia
FREUDIAN THEORY1/terapia
Limites: Seres Humanos
Feminino
Responsável: AR392.1 - Biblioteca


  7 / 1018 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Rocha, José Joaquim Ribeiro da
Texto completo
Id: lil-779760
Autor: Almeida, Ana Luiza Normanha Ribeiro de; Bernardes, Mário Vinícius Angelete Alvarez; Feitosa, Marley Ribeiro; Peria, Fernanda Maris; Tirapelli, Daniela Pretti da Cunha; Rocha, José Joaquim Ribeiro da; Feres, Omar.
Título: Serological under expression of microRNA-21, microRNA-34a and microRNA-126 in colorectal cancer
Fonte: Acta cir. bras;31(supl.1):13-18, 2016. tab, graf.
Idioma: en.
Resumo: PURPOSE: This paper describes the ability of miRNA value predict oncological outcomes in CRC patients and correlates to clinical and pathologic variables. METHODS: We prospectively analyzed the serological expression of microRNA-21, microRNA-34a, and microRNA-126 in 37 stage II - IV CRC patients and correlate to seven fit counterparts. Serological microRNAs were extracted using the miRNeasy Mini Kit(r) (Qiagen, Hilden, Germany). Quantification of microRNAs was performed using TaqMan Master Mix(r) reagent (Applied Biosystems, USA). RESULTS: We obtained serological underexpression microRNA-21, microRNA-34a, and microRNA-126 in CRC group. However, miRNAs serological values do not impact prognosis. Furthermore, miRNAs was not influenced by CEA values, TNM staging, and histological subtype. CONCLUSION: Despite lower expression of miR-21, miR-34a and miR-126 in the CRC group, no association with poor prognosis was found.
Descritores: Carcinoma/sangue
Neoplasias Colorretais/sangue
Adenoma/sangue
MicroRNAs/sangue
-Prognóstico
Valores de Referência
Carcinoma/genética
Neoplasias Colorretais/genética
Antígeno Carcinoembrionário/sangue
Biomarcadores Tumorais/sangue
Adenoma/genética
Estudos de Casos e Controles
Estudos Prospectivos
Fatores Etários
Reação em Cadeia da Polimerase em Tempo Real
Recidiva Local de Neoplasia
Estadiamento de Neoplasias
Limites: Seres Humanos
Masculino
Feminino
Responsável: BR1.1 - BIREME


  8 / 1018 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Rocha, José Joaquim Ribeiro da
Texto completo
Id: biblio-837691
Autor: Carvalho, Thais Inácio de; Novais, Paulo Cezar; Lizarte Neto, Fermino Sanches; Sicchieri, Renata Danielle; Rosa, Marcella Suelma Torrecillas; Carvalho, Camila Albuquerque Mello de; Tirapelli, Daniela Pretti da Cunha; Peria, Fernanda Maris; Rocha, José Joaquim Ribeiro da; Féres, Omar.
Título: Analysis of gene expression EGFR and KRAS, microRNA-21 and microRNA-203 in patients with colon and rectal cancer and correlation with clinical outcome and prognostic factors
Fonte: Acta cir. bras;32(3):243-250, Mar. 2017. tab, graf.
Idioma: en.
Resumo: Abstract Purpose: To evaluate the expression of EGFR, KRAS genes, microRNAs-21 and 203 in colon and rectal cancer samples, correlated with their age at diagnosis, histological subtype, value of pretreatment CEA, TNM staging and clinical outcome. Methods: Expression of genes and microRNAs by real time PCR in tumor and non-tumor samples obtained from surgical treatment of 50 patients. Results: An increased expression of microRNAs-21 and 203 in tumor samples in relation to non-tumor samples was found. There was no statistically significant difference between the expression of these genes and microRNAs when compared to age at diagnosis and histological subtype. The EGFR gene showed higher expression in relation to the value of CEA diagnosis. The expression of microRNA-203 was progressively lower in relation to the TNM staging and was higher in the patient group in clinical remission. Conclusions: The therapy of colon and rectum tumors based on microRNAs remains under investigation reserving huge potential for future applications and clinical interventions in conjunction with existing therapies. We expect, based on the exposed data, to stimulate the development of new therapeutic possibilities, making the treatment of these tumors more effective.
Descritores: Neoplasias Colorretais/genética
Adenocarcinoma/genética
Expressão Gênica
Proteínas Proto-Oncogênicas p21(ras)/análise
Genes ras
Genes erbB-1
MicroRNAs/análise
-Neoplasias Colorretais/patologia
Neoplasias Colorretais/tratamento farmacológico
Adenocarcinoma/patologia
Adenocarcinoma/tratamento farmacológico
Antígeno Carcinoembrionário/análise
Biomarcadores Tumorais/análise
Estudos Prospectivos
Fatores Etários
Resultado do Tratamento
Reação em Cadeia da Polimerase em Tempo Real
Estadiamento de Neoplasias
Limites: Seres Humanos
Masculino
Feminino
Meia-Idade
Idoso
Idoso de 80 Anos ou mais
Responsável: BR1.1 - BIREME


  9 / 1018 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Id: lil-774459
Autor: Arias Beatón, Ernesto; Arias Beatón, Martha Beatriz; Tellería León, Yoryana Elena; Causa Torres, Yosvanis.
Título: Cáncer de mama en una paciente de 21 años / Breast cancer in a 21 years patient
Fonte: Medisan;20(1), ene.-ene. 2016.
Idioma: es.
Resumo: Se presenta el caso clínico de una paciente de 21 años de edad, quien acudió a la consulta de Oncología del Hospital Gubernamental de Mbabane en Suazilandia por presentar un nódulo en la mama derecha con manifestaciones de dolor intenso desde hacía 1 mes. Fue remitida a la consulta de Cirugía donde le realizaron una biopsia con aguja gruesa, cuyo resultado indicó la presencia de un carcinoma ductal invasivo, clasificado en estadio IIIB al realizar los exámenes complementarios necesarios. La paciente fue trasladada a Sudáfrica para recibir quimioterapia neoadyuvante, con la cual obtuvo mejoría evolutiva clínica y humoral, evidenciada por la reducción del tumor y las cifras del marcador tumoral CA 15-3.

The case report of a 21 years patient who went to the Oncology service in the Government Hospital of Mbabane in Suaziland is presented. She had a nodule in her right breast with manifestations of acute pain for a month. She was referred to the Surgery service where she underwent a core-needle biopsy whose result indicated the presence of a ductal invasive carcinoma, classified in IIIB stage when carrying out the necessary complementary tests. The patient was transferred to South Africa to receive neoadyuvant chemotherapy, with which clinical and humoral response was obtained which was evidenced by tumor reduction and the values of the tumoral marker CA 15-3.
Descritores: Neoplasias da Mama
Quimioterapia Adjuvante
Carcinoma Ductal de Mama/tratamento farmacológico
-Biomarcadores Tumorais
Responsável: CU418.1 - Centro Provincial de Información de Ciencias Médicas de Santiago de Cuba


  10 / 1018 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Livramento, José Antonio
Machado, Luís dos Ramos
Livramento, José Antonio
Id: lil-179840
Autor: Livramento, José Antonio.
Título: Granuloma ou neoplasia? LCR: aspectos diagnósticos / Granuloma or neoplasm? CSF: diagnostic aspects
Fonte: In: Machado, Luís dos ramos; Livramento, José Antonio; Netto, Antonio Spina-França; Nóbrega, José Paulo Smith. Neuroinfecçäo 96. Säo Paulo, Clínica Neurológica HC/FMUSP, 1996. p.64-64, tab.
Idioma: pt.
Conferência: Apresentado em: Simpósio Neuroinfecçäo-96, Säo Paulo, 19-20 abr. 1996.
Descritores: Neoplasias do Sistema Nervoso Central/líquido cefalorraquidiano
Granuloma/líquido cefalorraquidiano
-Imuno-Histoquímica
Sensibilidade e Especificidade
Neoplasias do Sistema Nervoso Central/sangue
Granuloma/sangue
Diagnóstico Diferencial
Biomarcadores Tumorais
Limites: Seres Humanos
Responsável: BR1.1 - BIREME
BR1.1/2736.09; BR599.1; 616.8, C641n, AG. 10001010675



página 1 de 102 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde